Dechra Veterinary Products US and the Dechra
D logo are registered trademarks of Dechra
Pharmaceuticals PLC.
Your smaller patients can now receive the same effective,
FDA- approved treatment for their Cushing's syndrome as you've
trusted for your larger patients.
VETORYL Capsules are the only FDA veterinary-approved treatment
for pituitary-dependent and adrenal-dependent hyperadrenocorticism
in dogs (Cushing's syndrome). They contain the active ingredient
trilostane, which blocks the excessive production of cortisol.
They may be small,
but their treatment is now mighty.
VETORYL
®
Capsules (trilostane)
are now available in a 5mg strength.
866-933-2472 | www.dechra-us.com | support@dechra.com
24 Hour Technical Support:
VETORYL is a trademark of Dechra LTD. ©2015, Dechra Ltd.
NADA 141-291, Approved by FDA
CAUTION: Federal law restricts this drug to use by or on the order of licensed veterinarian.
1
http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm049823.htm
As with all drugs, side effects may occur. In f eld studies and post-approval experience, the most common side effects reported were:
anorexia, lethargy/depression, vomiting, diarrhea, elevated liver enzymes, elevated potassium with or without elevated sodium, elevated
BUN, decreased Na/K ratio, hypoadrenocorticism, weakness, elevated creatinine, shaking, and renal insuff ciency. In some cases, death
has been reported as an outcome of these adverse events. VETORYL Capsules are not for use in dogs with primary hepatic or renal
disease, or in pregnant dogs. Refer to the prescribing information for complete details or visit www.Dechra-US.com.